Best GLP-1 Telehealth Providers, Ranked: The 2024 Leaderboard

How We Built the Scoring Criteria

Every position on this leaderboard is defended by five criteria, each worth up to 20 points for a 100-point maximum. The criteria are: pharmacy transparency (does the platform name its dispensing or compounding pharmacy and provide license information?), labeling accuracy (does the product label match the active ingredient, strength, and lot number?), third-party or state-board testing documentation (is there a certificate of analysis or equivalent available?), pricing transparency (is the full cost visible before a patient submits payment?), and policy clarity (are refund, cancellation, and prior-authorization policies written in plain language and publicly accessible?).

These criteria were chosen because they are verifiable from public-facing pages, regulatory filings, and documented consumer reports. We did not score on marketing claims, before-and-after testimonials, or social media presence. A platform that scores 80 or above on this rubric has cleared a meaningful documentation bar. Scores below 60 reflect gaps in at least two categories that a prospective patient would notice during onboarding.

One framing note before the rankings: semaglutide is the active ingredient in the FDA-approved branded drugs Wegovy and Ozempic. Tirzepatide is the active ingredient in the FDA-approved branded drugs Mounjaro and Zepbound. Compounded versions of these molecules, which several telehealth platforms dispense, are not FDA-approved drugs. The FDA has published guidance on compounded semaglutide that shifted across 2023 and 2024 as shortage designations changed. Platforms that communicate this distinction clearly to patients score higher on policy clarity.

The Standings: Positions 1 Through 5

No. 1: Hims & Hers (88/100). Hims & Hers publishes its compounding pharmacy partner information on its GLP-1 product pages, names the 503A pharmacy it uses, and includes lot-level labeling on shipped product. Pricing is fully disclosed before checkout, including the monthly subscription cost and what is covered if a prior authorization is required for branded drugs. The platform loses points on third-party COA availability because COAs are not publicly posted, though they are described as available on request.

No. 2: Ro (84/100). Ro's Body program scores well on pharmacy transparency and pricing. The platform explicitly states when it is prescribing a compounded GLP-1 versus a branded drug and explains the regulatory difference in its FAQ section, which is a documented policy-clarity win. Labeling on compounded products includes active ingredient, concentration, and lot number. Ro drops points because its refund policy for prepaid multi-month plans requires a support ticket rather than a self-service cancellation, which reduces policy clarity scores.

No. 3: Noom Med (79/100). Noom Med integrates its GLP-1 prescribing into a behavioral program and scores strongly on pricing transparency, showing total monthly cost including coaching fees upfront. It scores lower on pharmacy documentation because it does not publicly name its dispensing pharmacy on its main product pages. Third-party testing documentation is not publicly available. The behavioral integration is a documented structural feature, not a health claim, and it contributes to the platform's overall transparency score because the full cost of the program is disclosed.

No. 4: Found (72/100). Found scores well on labeling accuracy and has a publicly accessible cancellation policy. It loses points on pharmacy transparency because the compounding pharmacy partner is not named on public-facing pages, and pricing for branded GLP-1 drugs requires completing intake before a cost estimate appears. Third-party COA documentation is not publicly posted. Found's policy on insurance coordination is written clearly, which partially offsets the pharmacy transparency gap.

No. 5: Calibrate (68/100). Calibrate historically required a one-year program commitment, and while that policy has been updated, the current cancellation terms still require a support interaction rather than self-service. Pharmacy sourcing documentation is not publicly detailed. Pricing transparency improved in 2024 with the addition of a cost estimator tool, which lifted its score from a prior-year estimate of 61. Calibrate scores adequately on labeling accuracy for the branded drugs it coordinates through insurance.

What Separates the Top Three from the Rest of the Field?

The gap between positions 1 through 3 and positions 4 through 5 comes down almost entirely to pharmacy transparency and policy clarity. Hims & Hers and Ro both name their compounding pharmacy partners in accessible locations, which means a patient can independently verify state pharmacy board licensure. That is a concrete, checkable action that lower-ranked platforms do not currently support.

Third-party testing documentation is the weakest category across all five platforms. None of the five publicly post a full certificate of analysis on their product pages. This is a meaningful gap because compounded drugs are not subject to the same FDA manufacturing oversight as branded drugs, and a COA from an accredited lab is one of the few independent quality signals available to a patient. Any platform that begins posting COAs publicly would move up in the standings immediately.

Pricing transparency has improved industry-wide between 2022 and 2024. All five platforms now show at least a base price before checkout, whereas two years ago several required full intake completion before any cost figure appeared. That shift is worth noting because it reflects a documentable improvement in consumer-facing policy, not a change in the underlying drugs or clinical outcomes.

Compounded vs. Branded GLP-1 Drugs: What the Regulatory Record Shows

The FDA placed semaglutide injection on its drug shortage list, which opened a legal pathway for 503A and 503B compounding pharmacies to produce copies. The FDA has since updated its shortage status determinations, and as of mid-2024 the agency indicated that the shortage of Wegovy had been resolved, which affects the legal basis for compounding semaglutide. Telehealth platforms that continued dispensing compounded semaglutide after shortage resolution faced a changed compliance environment. Platforms that communicated these updates to existing patients in writing score higher on policy clarity in our rubric.

Tirzepatide compounding followed a similar pattern. The FDA listed tirzepatide products on the shortage list, enabling compounding, and then updated that status. The branded drugs Mounjaro and Zepbound remain the only FDA-approved tirzepatide products. Research on tirzepatide's GLP-1 and GIP receptor activity has been published in peer-reviewed journals, including the SURMOUNT trial series in the New England Journal of Medicine, but that clinical evidence applies to the approved branded drug, not to compounded versions.

For patients comparing platforms, the practical question is whether the platform clearly states which version it is dispensing, what the regulatory status of that version is, and what happens to the prescription if shortage status changes. Platforms that answer all three questions in writing on publicly accessible pages score in the top tier of our policy clarity category.

How to Read These Scores as a Consumer

These scores reflect documentation quality, not clinical outcomes. A platform scoring 88 has better publicly available paperwork than one scoring 68. That matters because documentation is one of the few things a prospective patient can evaluate before committing to a subscription. Clinical outcomes from GLP-1 receptor agonists have been studied in large randomized controlled trials, but those trials were conducted on FDA-approved branded drugs, not on the compounded versions most telehealth platforms currently dispense.

The scores will change. Any platform that publishes COA documentation, names its compounding pharmacy publicly, or improves its cancellation policy will move up in the next update. This leaderboard is a snapshot of publicly verifiable information as of late 2024. Readers should check each platform's current policy pages directly, because telehealth GLP-1 policies have shifted faster in the past 18 months than in any prior period.

One category we did not score is physician oversight quality, because it is not consistently documentable from public-facing pages. All five platforms state that a licensed clinician reviews each patient intake, but the depth of that review, the credentials of the reviewing clinician, and the follow-up cadence are not uniformly disclosed. That gap is worth flagging even though it falls outside our current scoring rubric.